Farmacovigilancia en México
Pharmacovigilance is the activity related with the detection, evaluation, understanding and prevention of adverse events, adverse reactions or the suspection of these, of events supposedly attributable to vaccination or immunization; or any other safety problem related with the use of drugs and vacc...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2017 |
| País: | México |
| Institución: | Universidad Autónoma de Zacatecas |
| Repositorio: | Repositorio Institucional Caxcán |
| Idioma: | español |
| OAI Identifier: | oai:http://ricaxcan.uaz.edu.mx:20.500.11845/2527 |
| Acceso en línea: | http://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/2527 |
| Access Level: | acceso abierto |
| Palabra clave: | BIOLOGIA Y QUIMICA [2] Farmacovigilancia México reacciones adversas a medicamentos notificaciones Pharmacovigilance adverse reactions to drugs |
| Sumario: | Pharmacovigilance is the activity related with the detection, evaluation, understanding and prevention of adverse events, adverse reactions or the suspection of these, of events supposedly attributable to vaccination or immunization; or any other safety problem related with the use of drugs and vaccines. The aim of this study is to present a review on the pharmacovigilance work carried out in Mexico and the current problems it faces. In this regard, a systematic review was carried out in bibliographic databases (PubMed/MEDLINE, Science), a documentary analysis in public magazines and documented information by the World Health Organization, the Federal Commission for the Protection Against Sanitary Risks (COFEPRIS) and the National Pharmacovigilance Centre (CNFV). In Mexico, Pharmacovigilance starts at the end of the 1980s, and in 1995 is when the National Pharmacovigilance Centre was created after 68 events of suspected adverse drug reaction were reported. Almost a decade after, Pharmacovigilance acquires greater interest due to outreach and education campaigns, resulting in an increase in notifications received in the National Pharmacovigilance Centre in 2005 with 7 950 reports of suspected adverse reactions, and by 2013 were received 35 386 reports. Nowadays, the main challenge is the improvement in the quality of information in these reports. In the last year, 49.3 % of the reports were grade 2 and 0.67 % were grade 3. Notifications with insufficient information are of little use to set a precedent of it or give proper follow up to an adverse reaction to a drug. Results shown that the tasks of promoting Pharmacovigilance in the country have been successful; however, there is a need to work on refining the documentation of the whole process. |
|---|